# Delft Advanced Biorenewables

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/delft-advanced-biorenewables

- Industry: Biotechnology
- Headquarters: Delft, Netherlands
- Website: www.dab.bio
- Total disclosed funding: $2.2M
- Latest round: Series A (May 24, 2019)
- Investors on record: 2

## About

Delft Advanced Biorenewables specializes in innovative fermentation technology to optimize biobased production processes, enhancing efficiency and sustainability across various industries.Founded in 2012 in Delft, Netherlands, Delft Advanced Biorenewables focuses on advanced fermentation solutions. The company raised EUR 2 million in Series A funding in May 2019 from FORWARD.one Management BV and InnovationQuarter, marking a pivotal moment in its growth. The CEO, Eric Van Der Meer, leads the company as it aims to serve diverse clients with its cutting-edge technology.DAB.bio specializes in innovative fermentation technology designed to enhance cost efficiency and productivity in large-scale fermentative processes. The core product, FAST (Fermentation Accelerated by Separation Technology) system, allows continuous production by enabling the simultaneous separation and removal of target compounds. This technology addresses the limitations of traditional fermentation methods and serves clients in pharmaceuticals, chemicals, and food production across North America, Europe, and Asia, facilitating a transition to sustainable production methods.DAB.bio's revenue model consists primarily of technology licensing and engineering support services related to its FAST technology. Partnerships with clients engage DAB.bio for process development, optimization, and scale-up services, encompassing various agreements such as fixed licensing fees and milestone payments, aligning with the specific needs of each client, thus providing substantial value in biobased production processes.Delft Advanced Biorenewables plans to utilize the EUR 2 million raised in May 2019 to enhance its product offerings and expand into new markets. The company aims to develop new products within the FAST system and explore opportunities in untapped regions, targeting significant markets in Asia and North America by the end of 2024. This funding will support ongoing research and development efforts, ensuring that DAB.bio remains competitive while meeting the evolving needs of its clients.

## Funding rounds

- Series A, May 24, 2019, $2.2M — InnovationQuarter, FORWARD.one Management

## Investors

- InnovationQuarter (https://capitalatlas.ai/funds/innovationquarter) — Series A
- FORWARD.one Management (https://capitalatlas.ai/funds/forward-one-management) — Series A